Войти в систему Зарегистрироваться бесплатно

Midatech Pharma Plc Акции в обращении

Что обозначает Акции в обращении в Midatech Pharma Plc?

Акции в обращении Midatech Pharma Plc является 63.381M

Какое определение для Акции в обращении?



Акции в обращении - это все акции корпорации или финансового актива, которые были разрешены, выпущены и приобретены инвесторами и находятся в их собственности.

Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.

Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.

Акции в обращении компаний в Health Care сектор на LSE по сравнению с Midatech Pharma Plc

Что делает Midatech Pharma Plc?

Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Компании с акции в обращении похож на Midatech Pharma Plc